US 10835595
PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
granted A61KA61K2039/505A61K2039/53
Quick answer
US patent 10835595 (PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy) held by Inovio Pharmaceuticals, Inc. expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Inovio Pharmaceuticals, Inc.
- Grant date
- Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2039/505, A61K2039/53, A61K2039/54, A61K2039/545